Navigation Links
Amniotic membrane used to repair human articular cartilage
Date:6/23/2010

"The objective was to evaluate the utility of cryo-preserved human amniotic membrane (HAM) as a support for repairing human articular cartilage injuries, which have a very limited capacity for self-healing", Francisco J. Blanco, lead author of the study and a researcher at the Institute of Biomedical Research of La Corua (INIBIC), tells SINC.

The results, which have been published in the journal Cell and Tissue Banking, show that cryo-preserved HAM is useful as a scaffold for growing human chondrocytes in cell therapy and for repairing human cartilage injuries. "It provides a more regular surface and fills in the cavities and fissures", explains Blanco.

The authors cultivated the chondrocytes (cells that form part of the cartilaginous tissue), isolated from human articular cartilage, on the amniotic membrane over a period of three and four weeks. The amniotic membranes were used to develop 44 repair models of arthritic human articular cartilage in vitro, which was assessed between four and 16 weeks later.

The HAM also bonds well with the native cartilage. "In some models, we could not differentiate between where the native tissue stopped and the neo-synthesised tissue began", says the expert. This tissue had a fibrous appearance and high cellular density (cellularity), which in some cases was greater than that of the actual native cartilage.

The use of differentiated chondrocytes is a useful therapeutic option for repairing articular cartilage injuries. However, there are limitations to implanting these cells, since many patients will be ruled out due to their lack of healthy chondrocytes, and this technique also causes additional damage to the joint.

"Transplanting chondrocytes cultivated on different natural or synthetic 'scaffolds' is used today in cell tissue engineering. The HAM has sparked great interest over recent years, above all in the field of regenerative medicine", concludes Blanco.

Clinical solutions to osteoarthritis

Osteoarthritis (OA) is a major articular pathology that is characterised by alteration of the cartilage and the bone that supports it, the subchondral bone. As the current pharmacological and surgical treatments have only palliative effects, cell therapy is a new clinical approach for repairing damaged or destroyed tissues.

HAM has many clinical advantages as a support it is an anti-microbial, anti-angiogenic, anti-tumour tissue, which reduces inflammation and pain and improves scarring. In addition, the amnios of the HAM has no immune response, meaning there are no risks associated with transplanting it, and it contains many of the components of natural cartilage.


'/>"/>

Contact: SINC
info@plataformasinc.es
34-914-251-820
FECYT - Spanish Foundation for Science and Technology
Source:Eurekalert  

Related medicine news :

1. Amniotic fluid cells more efficiently reprogrammed to pluripotency than adult cells
2. Biocell Center Corporation Partners with New Englands Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation
3. Protein lets brain repair damage from multiple sclerosis, other disorders
4. Blocking DNA repair protein could lead to targeted, safer cancer therapy
5. Potential New Source of Stem Cells for Heart Repair
6. Research team documents benefits of endovascular stent repair for traumatic aortic injury
7. Study links microRNA to shut-down of DNA-repair genes
8. Stem cells from surgery leftovers could repair damaged hearts
9. Cedars-Sinai study examines regional use of minimally invasive repair of aneurysms
10. Stirling Dental Laboratory, Experts in Emergency Denture Repair Service, Gives Back to Community
11. Newly identified proteins critical to FA pathway DNA repair function
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Amniotic membrane used to repair human articular cartilage
(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology: